Evidence shows that the PI3K‐AKT signaling pathway is an emerging target for many new therapeutic agents for patients with ER+ breast cancer.[29, 36] Here, we found a novel regulatory mechanism involving MIR497HG and ERα/PI3K‐AKT interactions. This evidence concerns the gene ESR1 and breast carcinoma.